Current stock page

Financial Data

RCUS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

RCUSArcus Biosciences, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$17.43−$0.34 (−1.91%)

Latest quote

  • Momentum
    34
  • Value
    43
  • Quality
    41
  • Risk resilience
    42
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$9M$41M$17M$33M$26M$160M$28M$26M
Gross Profit$9M$41M$15M$30M$24M$160M$28M$26M
Operating Income-$131M-$96M-$134M-$114M-$142M-$8M-$122M-$103M
Net Income-$128M-$91M-$128M-$98M-$135M-$8M-$112M-$94M
EPS-$1-$0.72-$1.02-$0.92-$1.27-$0.08-$1.14-$1.03
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$88M-$119M-$138M-$120M-$97M-$133M-$132M-$100M
Capital Expenditure$0$0$0-$1M$0$0-$1M-$1M
Free Cash Flow-$88M-$119M-$138M-$121M-$97M-$133M-$133M-$101M
Net Cash Provided By Operating Activities-$88M-$119M-$138M-$120M-$97M-$133M-$132M-$100M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$818M$924M$997M$1.14B$974M$1.08B$1.16B$1.15B
Total Debt$102M$114M$113M$112M$111M$109M$60M$60M
Cash And Cash Equivalents$151M$150M$201M$222M$238M$248M$192M$150M
Total Liabilities$460M$460M$473M$508M$538M$526M$625M$665M
Total Stockholders Equity$358M$464M$524M$631M$436M$549M$531M$485M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio6.37.536.243.454.861.841.51.94
P/S ratio22.21———————
Debt To Equity0.280.250.220.180.250.20.110.12
Free Cash Flow Yield-20.68%-13.60%-14.96%-22.23%-21.92%-33.84%-37.92%-18.74%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio6.37.536.243.454.861.841.51.94
P/S ratio22.21———————
Return On Equity-124.30%-97.41%-70.42%-55.94%-80.05%-55.74%-73.63%-58.35%
Debt To Equity0.280.250.220.180.250.20.110.12

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-4.76x
Pb6.2x
Revenue Growth Yoy-65.38%
EPS Growth Yoy21.26%
Gross Margin95.00%
Operating Margin-475.00%
ROE-90.04%
ROIC-75.04%
Debt To Equity0.32
FCF Yield-18.57%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$17.43
Volume1.14M
RSI (14)35.06
MACD-1.38
MACD signal-1.54
MACD histogram0.16
ADX (14)29.61
SMA (50)$22.62
SMA (200)$24.47
ATR (14)$1.21
Historical volatility (annualized)92.19%
Volume (20-day average)2.65M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score42/100
Beta1.56
Annual volatility62.65%
Max Drawdown-44.79%
Sharpe Ratio0.05
VaR (95%, 1-day)-6.21%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

RCUS Financial Data FAQ

What is Arcus Biosciences, Inc.'s revenue?

Arcus Biosciences, Inc.'s revenue is one of the core financial data points for RCUS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Arcus Biosciences, Inc.'s revenue growing?

Revenue growth shows whether Arcus Biosciences, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is RCUS's EPS?

RCUS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Arcus Biosciences, Inc.'s net income?

Arcus Biosciences, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Arcus Biosciences, Inc. generate?

Free cash flow shows how much cash Arcus Biosciences, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Arcus Biosciences, Inc. have?

Cash and debt help frame RCUS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.